Scotia Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$16.1M Sell
127,501
-15,431
-11% -$2.03M 0.06% 174
2026
Q1
$19.9M Buy
142,932
+11,247
+9% +$1.57M 0.08% 137
2025
Q4
$16.2M Buy
131,685
+4,284
+3% +$521K 0.07% 160
2025
Q3
$14.1M Sell
127,401
-7,667
-6% -$871K 0.06% 170
2025
Q2
$15M Sell
135,068
-17,090
-11% -$1.82M 0.07% 157
2025
Q1
$17M Sell
152,158
-10,591
-7% -$1.09M 0.09% 132
2024
Q4
$15M Buy
162,749
+14,125
+10% +$1.27M 0.08% 139
2024
Q3
$12.5M Sell
148,624
-1,568
-1% -$120K 0.07% 155
2024
Q2
$10.3M Sell
150,192
-39,741
-21% -$2.65M 0.06% 166
2024
Q1
$13.9M Sell
189,933
-5,429
-3% -$417K 0.08% 140
2023
Q4
$15.8M Buy
195,362
+2,231
+1% +$174K 0.1% 121
2023
Q3
$14.5M Sell
193,131
-1,495
-0.8% -$115K 0.1% 123
2023
Q2
$15M Sell
194,626
-12,459
-6% -$994K 0.1% 123
2023
Q1
$17.2M Buy
207,085
+24,705
+14% +$2.05M 0.13% 113
2022
Q4
$15.7M Sell
182,380
-44,014
-19% -$3.49M 0.12% 113
2022
Q3
$14M Buy
226,394
+42,724
+23% +$2.69M 0.11% 115
2022
Q2
$11.4M Sell
183,670
-1,191
-0.6% -$73.7K 0.08% 144
2022
Q1
$11M Buy
184,861
+48,592
+36% +$3.11M 0.07% 160
2021
Q4
$9.89M Sell
136,269
-2,635
-2% -$181K 0.06% 172
2021
Q3
$9.7M Buy
138,904
+3,843
+3% +$270K 0.07% 159
2021
Q2
$9.3M Sell
135,061
-320
-0.2% -$21.4K 0.07% 170
2021
Q1
$8.75M Buy
135,381
+77,708
+135% +$5.01M 0.07% 162
2020
Q4
$3.36M Sell
57,673
-74,199
-56% -$4.48M 0.03% 268
2020
Q3
$8.33M Buy
131,872
+1,766
+1% +$122K 0.09% 141
2020
Q2
$10M Buy
130,106
+22,993
+21% +$1.76M 0.14% 105
2020
Q1
$8.01M Buy
107,113
+33,719
+46% +$2.33M 0.11% 111
2019
Q4
$4.77M Sell
73,394
-9,663
-12% -$629K 0.05% 178
2019
Q3
$5.26M Sell
83,057
-40,920
-33% -$2.67M 0.06% 159
2019
Q2
$8.38M Buy
123,977
+1,541
+1% +$101K 0.1% 122
2019
Q1
$7.96M Sell
122,436
-3,429
-3% -$228K 0.1% 127
2018
Q4
$7.87M Sell
125,865
-43,562
-26% -$3.04M 0.12% 113
2018
Q3
$13.1M Sell
169,427
-25,229
-13% -$1.91M 0.17% 88
2018
Q2
$14.6M Buy
194,656
+5,660
+3% +$400K 0.2% 83
2018
Q1
$14.2M Buy
188,996
+18,792
+11% +$1.49M 0.2% 84
2017
Q4
$12.2M Buy
170,204
+1,910
+1% +$145K 0.16% 94
2017
Q3
$13.6M Buy
168,294
+21,883
+15% +$1.67M 0.19% 78
2017
Q2
$10.4M Buy
146,411
+13,078
+10% +$870K 0.17% 91
2017
Q1
$9.06M Sell
133,333
-15,679
-11% -$1.1M 0.15% 99
2016
Q4
$10.7M Sell
149,012
-28,790
-16% -$2.14M 0.17% 96
2016
Q3
$14M Sell
177,802
-44,678
-20% -$3.63M 0.26% 74
2016
Q2
$18.6M Sell
222,480
-18,331
-8% -$1.63M 0.38% 57
2016
Q1
$22.1M Buy
240,811
+23,056
+11% +$2.08M 0.48% 49
2015
Q4
$21.1M Hold
217,755
0.48% 44
2015
Q3
$21.4M Buy
217,755
+16,501
+8% +$1.83M 0.48% 40
2015
Q2
$23.2M Buy
201,254
+32,666
+19% +$3.57M 0.47% 39
2015
Q1
$16.5M Sell
168,588
-1,342
-0.8% -$136K 0.43% 49
2014
Q4
$16M Buy
169,930
+33,960
+25% +$3.51M 0.42% 50
2014
Q3
$14.5M Buy
135,970
+10,362
+8% +$1.01M 0.31% 57
2014
Q2
$10.4M Buy
125,608
+54,818
+77% +$4.27M 0.23% 73
2014
Q1
$5.02M Buy
70,790
+758
+1% +$59.4K 0.11% 113
2013
Q4
$5.26M Buy
70,032
+49,012
+233% +$3.41M 0.13% 105
2013
Q3
$1.32M Sell
21,020
-90,380
-81% -$5.4M 0.04% 229
2013
Q2
$5.71M Buy
+111,400
New +$5.81M 0.22% 73

Other funds holding GILD

Scotia Capital's GILD Position: Q2 2026 in Review

Scotia Capital reduced its Gilead Sciences (GILD) stake by 11% in Q2 2026, selling an estimated $2.03M and leaving 127,501 shares worth $16.1M. The position accounts for 0.06% of the portfolio, ranked #174.

Scotia Capital first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $23.2M in Q2 2015. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Scotia Capital held 127,501 shares of Gilead Sciences worth $16.1M as of Q2 2026.
  • Scotia Capital sold 15,431 Gilead Sciences shares in Q2 2026, an estimated $2.03M.
  • Gilead Sciences made up 0.06% of Scotia Capital's portfolio in Q2 2026, its #174 holding.
  • Scotia Capital first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Scotia Capital's Gilead Sciences position peaked at $23.2M in Q2 2015.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Scotia Capital's 13F filing for Q2 2026, filed 11 Aug 2026.